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Abstract
Background:  Diabetic nephropathy, a major complication of diabetes, is characterized by
progressive renal injury and increased cardiovascular mortality. An increased urinary albumin
excretion due dysfunction of the glomerular barrier is an early sign of diabetic nephropathy. An
increased urinary excretion of higher molecular weight proteins such as IgM appears with
progression of glomerular injury. We aim here to study the prognostic significance of urine IgM
excretion in patients with type 1 diabetes mellitus (type 1 diabetic nephropathy).
Methods: This is an observational study of 139 patients with type1 diabetes mellitus (79 males and
60 females) under routine care at the diabetic outpatient clinic at the Lund University Hospital. The
median follow-up time was 18 years (1 to 22) years. Urine albumin and urine IgM concentration
were measured at time of recruitment.
Results: Overall 32 (14 male and 18 female) patients died in a cardiovascular event and 20 (11 male
and 9 female) patients reached end-stage renal disease. Univariate analysis indicated that patient
survival and renal survival were inversely associated with urine albumin excretion (RR = 2.9 and
5.8, respectively) and urine IgM excretion (RR = 4.6 and 5.7, respectively). Stratified analysis
demonstrated that in patients with different degrees of albuminuria, the cardiovascular mortality
rate and the incidence of end-stage renal disease was approximately three times higher in patients
with increased urine IgM excretion.
Conclusion: An increase in urinary IgM excretion in patients with type 1 diabetes is associated
with an increased risk for cardiovascular mortality and renal failure, regardless of the degree of
albuminuria.
Background
Diabetic nephropathy (DN) develops in up to 30% of
patients who have had diabetes for more than 20 years
[1,2]. DN is characterized by persistent albuminuria, ele-
vated blood pressure, and progressive decline in renal
function [3]. Development of DN is associated with an
increased risk of cardiovascular (CV) complications and
mortality [4,5]. However, a large interindividual variation
in the rate of decline in kidney function and mortality has
been reported [3,6]. This highlights the need for identifi-
cation of risk factors and early predictors of progression.
An increased urinary albumin excretion is an early sign of
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DN. Impairment of the tubular protein reabsorption or in
the charge-selectivity of the glomerular filtration barrier
are probably the major causes of albuminuria in the early
stages of type 1 DN [7]. An impairment of the glomerular
size-selectivity and increased urine excretion of high
molecular weight (HMW) proteins are seen in advanced
stages of DN [8,9]. Increased urinary IgM excretion reflects
an abundance of highly non-selective pore pathways in
the glomerular filter [10]. Our studies on chronic glomer-
ular disease generally show an association between
increased urinary IgM excretion and poor kidney and
patient survival [11,12]. The present study aims to evalu-
ate the prognostic impact of increased urine IgM excretion
in comparison to degree of albuminuria in an unselected
population of patients with type 1 diabetes.
Methods
In this observational follow-up study, patients with type 1
diabetes mellitus regularly attending our out-patient
clinic at the Lund University Hospital were identified and
recruited prospectively between 1984 and 2003. Forty-six
(25 male and 21 female) patients had an albumin excre-
tion rate in the microalbuminuric range, 48 (25 male and
23 female) had a urinary albumin excretion rate in the
macroalbuminuric range, and 45 (29 male and 16 female)
patients had a urinary albumin excretion rate in the nor-
mal range. The level of albuminuria was confirmed in at
least two out of three consecutive urine samples. A total of
139 patients with type 1 diabetes were followed prospec-
tively until October 2007 or death. The study was
approved by the Ethics Committee at Lund University
Hospital, and all patients gave informed consent. The
patient characteristics are shown in Table 1. The median
age was 35 years (18 to 80), and the median serum creat-
inine was 85 μmol/l (42 to 486). Present medications and
blood pressure were taken from the patient records.
Causes of death were traced from the National Death Reg-
ister at the Swedish Board of Health and Welfare, and the
patients' hospital records [13], Table 2. CV death was clas-
sified as all deaths where unequivocal non-CV death was
not established. End-stage renal disease (ESRD) was
defined as start of renal replacement therapy (dialysis or
kidney transplantation) or serum creatinine >500 μmol/l.
Laboratory measurements
Glycosylated hemoglobin (HbA1c) was analyzed by high-
performance liquid chromatography. Serum and urinary
creatinine concentrations were analyzed by an enzymatic
method (creatinine-amidino-hydrolase; KODAK
EKTACHEM analyser, Instrument Kodak, NY, USA). Uri-
nary albumin concentration was measured on fresh urine
samples using turbidimetry (Cobas Mira S, Roche). The
detection limits was 5 mg/l, and the coefficient of varia-
tion was between 1% and 8%. Urine samples were kept at
-20°C until analysis for IgM in December 2006. Urine
IgM concentrations were measured by ELISA as described
elsewhere [10]. The lower detection limit for the urine
IgM assay is 1 μg/l; the intra-assay and inter-assay varia-
tion is 4.6% and 10.9%, respectively. Glomerular filtra-
tion rate (GFR) was estimated using the MDRD formula
[14,15], where eGFR = {186.3 × (serum creatinine mg/dl)-
1.154 × (age)-0.203 (× 0.742 if female).
Statistical analysis
Data are presented as median (range) or mean ± SE. The
patients groups were compared with non-parametric sta-
Table 1: Characteristic of 139 patients with type 1 diabetes divided according to initial degree of albuminuria into normo (45), micro 
(46), and macro (48).
Variable Normal Micro Macro P value
At baseline:
Sex (Male/Female) 44 (29/15) 46 (25/21) 49 (25/24) 0.3, ns
Age (years) 34 (2072) 35 (1880) 38 (2179) 0.09, ns
Duration of diabetes 11 (154) 18 (165) 25 (167) <0.001
S. creatinine (μmol/l) 74 (54110) 80 (42175) 103 (61486) <0.001
GFR (ml/min/1.73 m2) 91(45141) 78 (28144) 60(9105) <0.001
Urine IgM (mg/mmol·10-3) 6.7(1.731.8) 8.7(2.540) 11.5(2.8363) 0.009
HbA1c % 7.6(4.513.4) 8.8(5.513.2) 9.1(6.212.7) 0.01
ACEI/ARBs, n/n (%) 0/0 (0%) 3/3 (13%) 15/5 (40.8%) <0.001
MAP, mmhg 92(78110) 96(80127) 103(82133) <0.001
During follow-up:
Follow up time, years 19(222) 19(222) 9(122) 0.01
MAP, mmhg 93(73127) 99(78125) 103(73147) 0.005
HbA1c % 8.1(4.513.9) 8.0(5.011.1) 8.2(4.513.4) 0.61
ACEI/ARBs, n/n (%) 5/0 (11.4%) 9/15 (53.3%) 20/16 (76.6%) <0.001
CV-Mortality rate per patient-year 0.003994674 0.0110957 0.035836177 <0.001
Renal failure rate per patient-year 0 0.007407 0.032895 <0.001
Abbreviations: ACEI: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin II receptor antagonists; CV: cardiovascular; ESRD: End stage 
renal disease; GFR: glomerular filtration rate; HbA1c: glycosylated hemoglobin; MAP: Mean arterial blood pressure.BMC Medicine 2009, 7:39 http://www.biomedcentral.com/1741-7015/7/39
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tistical tests Mann-Whitney U and Kruskal-Wallis H tests.
The Fisher's exact test and Pearson Chi square (χ2) test
were used when appropriate. Incidence rate of ESRD and
mortality rate were calculated per person-year. Kaplan-
Meier curves were used for survival analysis. Univariate
Cox regression analysis was used to examine the baseline
variables predictive of CV mortality and ESRD. Results
described as relative ratios (RR) and the 95% confidence
intervals (95% CI). Due to sample size restriction, subse-
quent stratified analysis was conducted only to compare
the prognostic effect of albuminuria and IgM-uria. The
patients were divided into low and high IgM excretion
groups according to the median value (0.01 mg/mmol) of
urine IgM excretion. Microalbuminuria was defined as a
urinary albumin excretion rate of 3 to 20 mg/mmol; <3
mg/mmol was regarded as normal and >20 mg/mmol was
regarded as macroalbuminuria [16]. Statistical analyses
were performed using statistical package SPSS 13.0 (SPSS,
Chicago Illinois, USA). The level of statistical significance
was set at P values < 0.05.
Results
The median time to death or end of follow up by October
2007 was 18 years (1 to 22). During the follow up 38
patients died and 20 (11 male and 9 female) patients
developed ESRD. Six (1 male and 5 female) patients died
from non-CV events and 32 (14 male and 18 female)
patients in a CV event (Table 2). These 32 (14 male and
18 female) patients were included in a further analysis of
CV-mortality.
Univariate Cox-regression analysis identified the follow-
ing predictors of CV mortality: age (HR = 11.5, 95% CI 3.5
to 38, P < 0.001), duration of diabetes (HR = 7.8, 95% CI
3 to 20, P < 0.001), mean arterial blood pressure (HR =
3.6, 95% CI 1.6 to 8.1, P = 0.002), serum creatinine (HR
= 3.3, 95% CI 1.5 to 7.3, P = 0.004), eGFR (HR = 9.3, 95%
CI 3.3 to 27.0, P < 0.001), urinary albumin excretion (HR
= 2.9, 95% CI 1.7 to 5.0, P < 0.001) and urinary IgM excre-
tion (HR = 4.6, 95% CI 2.0 to 10.7, P < 0.001). The pre-
dictors of ESRD were: duration of diabetes (HR = 4.3, 95%
CI 1.6 to 12, P =0.005), mean arterial blood pressure (HR
= 3.9, 95% CI 1.4 to 10.8, P = 0.009), serum creatinine
(HR = 23.3, 95% CI 3.1 to 174, P = 0.002), GFR (HR =
12.4, 95% CI 2.9 to 54.0, P = 0.001), urinary albumin
excretion (HR = 5.8, 95% CI 2.4 to 14, P < 0.001) and uri-
nary IgM excretion (HR = 5.7, 95% CI 1.9 to 17, P  =
0.002). Stepwise multivariate Cox regression analysis
shows that urine IgM excretion, independently of the level
of albuminuria, predicts CV mortality and renal failure (P
= 0.004). There was no significant difference in CV mor-
tality between those treated and those not treated by ACE
inhibitors, (29.2% vs. 15.5%, P = 0.054) or between those
treated by ACEi or ARBs (35.1% vs. 22.6, P = 0.26).
Patient and renal outcome by degree of albuminuria
Table 1, shows the baseline and follow-up data of the 139
patients studied divided according to the degree of base-
line albuminuria. As expected, the duration of diabetes,
serum creatinine and blood pressure were significantly
higher in the macroalbuminuric group. During follow-up
there was no difference in HbA1c, and more patients with
macroalbuminuria received ACE inhibitors.
Cardiovascular mortality
Three patients in the normo-albuminuric and eight
patients in the microalbuminuric group died of a CV
event during the follow-up time, compared with 21
(36.8%) patients in the macroalbuminuric group (P  <
0.001). The risk of CV mortality was 3.6% per patient-year
in patients with macroalbuminuria compared with
approximately 1.1% in patients with microalbuminuria;
that is, the RR increment was 3.23 (Table 1).
Renal survival
Fifteen (30.6%) patients from the macroalbuminuric
group developed ESRD compared with only five (5.6%)
patients in the microalbuminuric group (P < 0.001). The
risk of ESRD was approximately 3.3% per patient-year in
patients with macroalbuminuria compared with approxi-
mately 0.7% in patients with microalbuminuria (RR 4.44,
Table 1).
Patient and renal outcome by degree of IgM-uria
Table 3 shows the baseline and follow-up data of the 139
patients studied divided according to baseline urine IgM
excretion. Patients with increased urine IgM excretion had
significantly increased urine albumin excretion, higher
blood pressure and higher serum creatinine compared
Table 2: Causes of death of 38 patients died during a median of 
18 years follow-up time of 139 patients with type 1 diabetes 
mellitus.
Cause No. (M/F)
Cardiovascular 32 (14/18)
Cardiac arrest 8 (3/5)
MI 12 (5/7)
Heart failure 3 (2/1)
Stroke 9 (4/5)
Malignancy 2(0/2)
Lung cancer 1 (0/1)
Uterus cancer 1 (0/1)
Sepsis 2(0/2)
Acute hypoglycemia 1(1/0)
Suicide 1(0/1)
Total 38(15/23)
Abbreviations: MI = Myocardial Infarction.BMC Medicine 2009, 7:39 http://www.biomedcentral.com/1741-7015/7/39
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with patients with low urine IgM excretion. The low IgM
group had a mean urine IgM concentration of 0.0055 ±
0.0017 mg/mmol, and the high IgM group had a mean
urine IgM concentration of 0.0258 ± 0.0457 mg/mmol.
There was no difference in follow-up glycemic control
between IgM groups, and patients with high IgM excretion
had a higher percentage of renoprotective treatment with
ACE inhibitors.
Cardiovascular mortality
Seven (9.9%) patients with low urinary IgM excretion
died from CV events during the follow-up time compared
with 25 (36.8%) patients with high urinary IgM excretion
(P  < 0.001). The risk of CV mortality was 2.9% per
patient-year in patients with high urine IgM excretion
compared with approximately 0.6% in patients with low
in IgM excretion (RR = 4.98, Table 3).
Renal survival
Sixteen (23.5%) patients from the high IgM group devel-
oped ESRD during the follow-up period compared with
only four (5.6%) patients with low urinary IgM excretion
(P = 0.003). The risk of ESRD was 2.2% per patient-year in
patients with high urinary IgM excretion compared with
approximately 0.35% in patients with low in IgM excre-
tion (RR = 6.4, Table 3).
Patient and renal outcome by degree of albuminuria and 
IgM-uria
Cardiovascular mortality
Patients with microalbuminuria and high urine IgM excre-
tion had 2.1% per patient-year risk for CV mortality, com-
pared with approximately 0.46% in those with low IgM
excretion (RR = 4.6, Table 4). Patients with macroalbu-
minuria and high urine IgM excretion had 4.8% per
patient-year risk for CV mortality, compared with 1.7% in
those with low IgM excretion, (RR = 2.8, Table 4). Even
patients with normoalbuminuria and high urine IgM
excretion had significantly higher risk for CV mortality
compared with those with low IgM excretion (0.9% vs.
0.57% per patient-year, RR = 1.6, Table 4). The pattern of
cumulative patient survival by degree of albuminuria and
IgM-uria are show in Figure 1.
Renal survival
Patients with microalbuminuria and high urine IgM excre-
tion had approximately 1.2% per patient-year risk for
renal failure, compared with approximately 0.48 in those
with low IgM excretion (RR = 2.4, Table 4). Patients with
macroalbuminuria and high urine IgM excretion had
5.3% per patient-year risk for renal failure, compared with
1.4% in those with low IgM excretion, (RR = 3.7, Table 4).
The pattern of cumulative renal survival by degree of albu-
minuria and IgM-uria is show in Figure 2.
Discussion
In this cohort of long-time follow-up (median 18 years) of
patients with type 1 diabetes, with and without diabetic
nephropathy, we found that patients with an increased
urinary IgM excretion had a higher mortality from CV
causes, and higher disease progression rate to ESRD com-
pared with patients with low urinary IgM excretion. In
accordance with other reports, this study demonstrates
that CV death due to atherosclerosis is the major cause of
Table 3: Characteristic of 139 patients with type 1 diabetes divided according to the median urine IgM level into low (<0.01 mg/mol) 
and high IgM (>0.01 mg/mol) groups.
Variable Low IgM group High IgM group P value
At baseline:
Sex (male/female) 71 (49/22) 68 (30/38) 0.003
Age (years) 35(1874) 37(2080) 0.05
Duration of diabetes (yr) 15 (165) 24 (167) 0.001
HbA1c % 8.3 (4.513.4) 9 (5.513.2) 0.06, ns
Albuminuria (mg/mmol) 3.6(0.23268) 21.3 (0.26640) <0.001
S. Creatinine μmol/l 78 (54216) 86 (42486) 0.009
GFR (ml/min/1.73 m2) 88 (27141) 67(9144) <0.001
MAP mmhg 93 (80120) 100 (78133) 0.004
ACEI/ARBs, n/n (%) 3/2 (7.1%) 15/6 (31%) <0.001
During follow-up:
Follow up time (years) 19 (222) 14 (122) <0.001
MAP mmhg 97 (73119) 103 (73147) 0.038
HbA1c (%) 8.25 (4.513.9) 8 (4.513.4)
0.7, ns
Albuminuria (mg/mmol) 1.3 (0.1676) 20.5 (0.11101) <0.001
ACEI/ARBs, n/n (%) 12/14 (37%) 22/17 (59%) 0.008
CV-Mortality rate per patient-year 0.005838 0.029104 <0.001
Renal failure rate per patient-year 0.003451 0.022161 0.003
Abbreviations: ACEI: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin II receptor antagonists; CV: cardiovascular; ESRD: End stage 
renal disease; GFR: glomerular filtration rate; HbA1c: glycosylated hemoglobin; MAP: Mean arterial blood pressure.BMC Medicine 2009, 7:39 http://www.biomedcentral.com/1741-7015/7/39
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mortality in diabetic patients. Furthermore, the mortality
was strongly associated with duration of diabetes mellitus
and the degree of albuminuria [3,4]. To our knowledge
our study is the first one investigating the impact of an
increased urine IgM excretion on DN disease progression
in type 1 diabetic patients.
We were able to show that the association of urine IgM
excretion with a higher risk for CV mortality and ESRD is
largely independent of the level of albuminuria. Patients
with DN and increased urine IgM excretion, either in the
micro or the macroalbuminuric stage, had at least a three-
fold higher risk of CV mortality and renal failure than
those with low urinary IgM excretion, (Table 4, Figures 1
and 2).
Previous studies suggest that the development of DN in
patients with type 1 diabetes is due to an early impairment
of charge selectivity of the glomerular filter. The size selec-
tivity dysfunction appears later, along with progression of
the disease [17]. Thus, albuminuria per se could be due to
impairment of glomerular charge or size selectivity, that
is, could reflect minor or severe glomerular damage
[18,19]. IgG-uria (molecular radius 55 Å), studied previ-
ously by others, is mainly due to an increased transport
through the large pores [17]. However, the very large pro-
tein measured in this study, IgM (molecular radius 120
Å), is able to pass the glomerular filtration barrier only
through very large defects (shunts) [10]. Thus, the occur-
rence of IgM in the final urine reflects a markedly
increased population of highly unselective glomerular
pathways and probably a more severe glomerular damage
[11,12].
An increase in renal vascular resistance, due to atheroscle-
rotic vascular disease, may induce ischemia and more
severe structural changes in the glomeruli, and cause an
increase in urinary excretion of HMW proteins through
Table 4: Patient and renal outcome of 139 patients with type 1 diabetes by degree of albuminuria and IgM-uria.
Stage of DN Baseline urine IgM 
excretion
Rate of renal failure 
per patient-year
CV-Mortality rate per 
patient-year
10 year Patient 
survival
10 year Renal survival
Normoalbuminuria (n 
= 44)
Low (n = 31) 0 0.005671 96.5% 100%
High (n = 13) 0 0.009009 91.7% 100%
Microalbuminuria (n = 
46)
Low (n = 24) 0.004750594 0.004577 95.7% 95.6%
High (n = 22) 0.011811024 0.021127 84.9% 87.5%
Macroalbuminuria (n = 
49)
Low(n = 16) 0.014354067 0.017167 73.9% 84%
High (n = 33) 0.052631579 0.048159 59.5% 53%
Cardiovascular mortality rate by albuminuria and urine IgM Figure 1
Cardiovascular mortality rate by albuminuria and urine IgM.BMC Medicine 2009, 7:39 http://www.biomedcentral.com/1741-7015/7/39
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such shunt-like pathways [20-23]. This may explain why
urinary IgM excretion correlates with CV events in this
cohort of type 1 diabetic patients.
Conclusion
While albuminuria is an early predictor of DN progres-
sion, we were able in this study to show that an increased
urinary IgM excretion in patients with DN was an inde-
pendent predictor of CV complications. However, further
studies are needed to evaluate the correlation between
urine IgM excretion and surrogate markers of atheroscle-
rosis in patients with CV disease and diabetes mellitus.
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